The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
Hulya Gungel,1 Ozen Ayranci Osmanbasoglu,1 Cigdem Altan,2 Deniz Oygar Baylancicek,3 Isil Basgil Pasaoglu2 1Istanbul Education and Research Hospital, Eye Clinic, 2Beyoglu Eye Education and Research Hospital, 3Kudret Eye Hospital, Istanbul, Turkey Aim: The objective of the study reported here was t...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/59bab0f174834088b532509789749b02 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Hulya Gungel,1 Ozen Ayranci Osmanbasoglu,1 Cigdem Altan,2 Deniz Oygar Baylancicek,3 Isil Basgil Pasaoglu2 1Istanbul Education and Research Hospital, Eye Clinic, 2Beyoglu Eye Education and Research Hospital, 3Kudret Eye Hospital, Istanbul, Turkey Aim: The objective of the study reported here was to evaluate the effect of ranibizumab on retinal circulation times and vessel caliber and to analyze the correlation of these factors with visual acuity (VA) prognosis in patients with age-related macular degeneration (AMD).Subjects and methods: This prospective cohort study included 52 eyes of 46 patients (mean age 73.5 years [standard deviation 7.7]; 28 males, 18 females). The study parameters were best-corrected visual acuity (BCVA), central macular thickness (CMT) (pre- and posttreatment: for 3 months after the last injection), retinal circulation times, diameter of retinal arteriole (DRA), and diameter of retinal vein (DRV) (pre- and posttreatment: after a loading dose of three consecutive injections of ranibizumab with a 4-week interval in the initial phase). The pretreatment, posttreatment measurements, and their differences were recorded for analyses. The injections were repeated when needed. Eyes were grouped into one of two groups according to VA recovery: Group 1, cases showing significant recovery of VA (n=21, 37%), and Group 2, cases showing preservation of VA (n=22, 42%) and deterioration of VA (n=11, 21%). Differences were compared statistically in and between groups. Logistic regression analysis was undertaken to determine the correlation of these parameters with VA recovery.Results: There was a significant reduction in DRA (P=0.007) and CMT levels (P=0.001) in both study groups after treatment. When the two groups were compared, the differences in pretreatment values of DRA (P=0.001), DRV (P=0.017), CMT (P=0.039), and mean BCVA (P=0.00) were found to be statistically significant. Posttreatment changes in DRA (P=0.013) and mean CMT (P=0.010) were found to be factors related to VA recovery by logistic regression analysis.Conclusion: Our findings reveal that ranibizumab treatment is associated with decrease in DRA, CMT, and significant improvement in VA recovery. Further, taking into account the cases in which VA was preserved, when needed, ranibizumab should be re-injected after the loading dose. Keywords: vessel caliber, prognosis, central macular thickness, retinal vein diameter, retinal arteriole diameter |
|---|